finance.yahoo.com
Positivefinance.yahoo.com ·
Amgen Amgn Gets Price Target
DogsWellbeing HealthDiseasesOverweight
Topic context
This topic has been covered 277131 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article discusses analyst price target changes and an upgrade for Amgen, a biotech firm. The commercial mechanism is weak: no concrete revenue/cost/margin impact is reported beyond analyst opinions. The primary sector is PHARMA_BIOTECH, but no supply chain or scarcity implications.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Piper Sandler reduced Amgen price target from $432 to $427, maintains Overweight.
- Freedom Broker upgraded Amgen to Buy from Hold, price target $375.
- Amgen's Q1 results met expectations despite seasonal weakness.
- Revenue growth potential cited from rare disease segment, particularly Uplizna.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
finance.yahoo.com
Aytu Aytu Q3 2026 Earnings
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com